肠道菌群
免疫系统
微生物群
肥胖
肠道微生物群
癌症
免疫学
炎症
生物
医学
生物信息学
内科学
作者
Matthieu Delaye,Adrien Rousseau,Léah Mailly-Giacchetti,Sandra Assoun,Harry Sokol,Cindy Neuzillet
标识
DOI:10.1016/j.pharmthera.2023.108442
摘要
Immune checkpoint inhibitors (ICI) have deeply changed the therapeutic management of a broad spectrum of solid tumors. Recent observations showed that obese patients receiving ICIs might have better outcomes than those with normal weight, while obesity was historically associated with a worse prognosis in cancer patients. Of note, obesity is associated with alterations in the gut microbiome profile, which interacts with immune and inflammatory pathways, both at the systemic and intratumoral levels. As the influence of the gut microbiota on the response to ICI has been repeatedly reported, a specific gut microbiome profile in obese cancer patients may be involved in their better response to ICI. This review summarizes recent data on the interactions between obesity, gut microbiota, and ICIs. In addition, we highlight possible pathophysiological mechanisms supporting the hypothesis that gut microbiota could be one of the links between obesity and poor response to ICIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI